Clinical Trials Research
|
|
- Diane Sullivan
- 6 years ago
- Views:
Transcription
1 Clinical Trials Research Miami Campus - Dr. Marc E Agronin, Principal Investigator Name of Study: Acadia (SERENE Study) ACP Description of Study: This is a phase II study testing to see if an investigational drug called Pimavanserin can be used to treat agitated and aggressive behavior in individuals with Alzheimer s disease. Indication: Agitation and aggression in Alzheimer s disease Recruiting Subjects Ages: 50 years or older Duration of Study: approximately 3 months Name of Study: Avanir 15-AVP /303 Description of Study: The TRIAD Study is a phase III study evaluating an investigational medication to see if it may reduce agitation in patients with dementia related to Alzheimer s disease. Indication: Dementia of the Alzheimer s type Recruiting Subjects Ages: years Duration of Study: approximately 4 months Name of Study: Avid (A16 Study) 18F-AV-1451-A16 Description of Study: The A16 study is testing an investigational imaging dye, 18F-AV-1451, to see if it can be used in PET imaging to identify a build-up of tau protein, an abnormality found in the brains of patients with Alzheimer s disease. The study will look at the relationship between the build-up of tau protein detected by the PET scan and the buildup detected by autopsy of the brain in end-of-life subjects. Indication: End Stage conditions (life expectancy < 6 months) Recruiting Subjects Ages: 50 years or older Duration of Study: approximately 6 months
2 Name of Study: Axovant RVT Description of Study: This is a phase II study testing an investigational medication called Intepirdine (RVT-101) to improve movement problems including gait and balance in individuals with certain forms of dementia. Indication: Gait impairment and Alzheimer s disease, dementia with Lewy bodies, or Parkinson s disease dementia Recruiting Subjects Ages: years Duration of Study: approximately 14 weeks Name of Study: Biogen (ENGAGE Study) 221AD301 - Immunotherapy Description of Study: The ENGAGE study is a phase III, global study assessing the efficacy and safety of the investigational medication Aducanumab (BIIB037). The goal is to determine whether the medication can slow the progression of symptoms in individuals with early Alzheimer's disease. Recruiting Subjects Ages: years Duration of Study: approximately 18 months Name of Study: Eli Lilly (GERAS-US Study) H8A-US-B004 Description of Study: The GERAS-US Study is collecting information from individuals with mild cognitive impairment or mild dementia due to Alzheimer s disease about the care involved in maintenance and treatment, including use of resources, types of care, and outcomes. The study s goal is to assess the total costs involved in individuals already seeking routine care, and to better understand overall care for earlier stages of the disease. Indication: Early stages of Alzheimer s disease Recruiting Subjects Ages: years Duration of Study: 36 months Name of Study: Eisai E2609-G Description of Study: This study is investigating a drug called Elenbecestat (E2609) in individuals with mild cognitive impairment (MCI) due to Alzheimer s disease or other early stages of mild Alzheimer s disease. The goal of the study is determine whether the drug reduces the amount of protein buildup in the brain of Alzheimer s patients, and if the potential reduction would in turn slow the progression of the disease and its associated memory loss. Duration of Study: approximately 29 months
3 Name of Study: Genentech (GN30009 Study) Description of Study: This study evaluates the use of an investigational imaging tracer, [ 18 F] MNI-798, as a diagnostic tool to identify Tau Tangles, an abnormal buildup of protein in the brain, in patients with prodromal, mild, and moderate Alzheimer s disease. The imaging agent may be used as a marker for disease progression in conjunction with PET imaging, and may allow doctors to see changes in the brains of patient who have problems with thinking and memory related to Alzheimer s disease. Indication: Prodromal, mild, and moderate Alzheimer s disease Recruiting Subjects Ages: years Duration of Study: 18 months Name of Study: ACRIN (Imaging Dementia - Evidence for Amyloid Scanning, IDEAS, Study) Description of Study: The IDEAS study is an observational study to determine the impact of amyloid PET scans on patient-oriented outcomes in those with mild cognitive impairment (MCI) or dementia. The study will look at whether knowing a patient s amyloid status significantly impacts long-term patient care and outcome. Amyloid plaques are sticky clumps of protein associated with Alzheimer s disease that can be seen in pictures of the brain. Indication: Dementia or MCI Recruiting Subjects Ages: 65 years or older Duration of Study: approximately 24 months Name of Study: IntraCellular (201 Agitation Study) ITI Description of Study: This is a phase III clinical trial testing the effectiveness and safety of an investigational medication (ITI-007), on treating symptoms of agitation associated with dementia in patients with probable Alzheimer s Disease. Indication: Probable Alzheimer s disease Recruiting Subjects Ages: 55 years or older Duration of Study: 2 months Name of Study: Neurim NEUP11-AD2 Description of Study: This is a phase II study evaluating the safety, tolerability, and efficacy of an investigational drug called Piromelatine in patients with mild Alzheimer s Disease. Piromelatine may have the potential to enhance sleeping quality and patterns, which has been shown to be positively associated with overall cognitive function. Indication: Mild Dementia due to Alzheimer s disease Recruiting Subjects Ages: years Duration of Study: approximately 7 months
4 Name of Study: Proclara NPT088-CL002 - Immunotherapy Description of Study: This is a phase I study assessing the safety and tolerability of the investigational drug NPT008 in patients with mild to moderate probable Alzheimer s disease. The drug is intended to target multiple types of misfolded proteins in the brain of Alzheimer s patients, all which have been linked to the pathology of neurodegenerative diseases and in combination may contribute to disease progression. Indication: Probable Alzheimer s disease Duration of Study: approximately 8 months Name of Study: Roche (CREAD Study) BN Immunotherapy Description of Study: This is a phase III global study evaluating the efficacy and safety of the investigational medication Crenezumab to assess if targeting beta-amyloid (which is implicated in the pathogenesis of Alzheimer s disease) early in the course of the disease can delay its progression. Indication: Prodromal to mild Alzheimer s disease Duration of Study: approximately 35 months Miami Campus - Dr. Shaun Corbett, Principal Investigator Name of Study: Axsome (CREATE-1 Study) AXS Description of Study: The CREATE-1 study is a phase III clinical trial evaluating the effectiveness and safety of an oral investigational medication AXS-02 (zoledronate) to see if it can help reduce lingering upper or lower limb pain in patients with Complex Regional Pain Syndrome (CRPS-1). Indication: Complex Regional Pain Syndrome (CRPS-1) Recruiting Subjects Ages: 18 years or older Duration of Study: 6 to 7 months Aventura Location- Dr. Julie Schwartzbard, Principal Investigator Name of Study: Allergan UBR-MD-02 Description of Study: This is a phase II clinical trial testing the effectiveness and safety of an investigational medication that targets single migraine attacks. The goal of the study is to see if the medication can provide acute treatment for moderate to severe migraines. Indication: Migraine with or without aura Recruiting Subjects Ages: years Duration of Study: 2-3 months
5 Name of Study: Biotie TOZ-CL06 Description of Study: This is a phase III clinical trial evaluating the safety and efficacy of a medication called Tozadenant, which may potentially decrease daily Wearing-Off periods in Levodopa-treated patients with Parkinson s disease. Indication: Parkinson s disease (PD) Recruiting Subjects Ages: years Duration of Study: Up to 62 weeks Name of Study: Eisai E2609-G Description of Study: This study is investigating a drug called Elenbecestat (E2609) in individuals with mild cognitive impairment (MCI) due to Alzheimer s disease or other early stages of mild Alzheimer s disease. The goal of the study is determine whether the drug reduces the amount of protein buildup in the brain of Alzheimer s patients, and if the potential reduction would in turn slow the progression of the disease and its associated memory loss. Duration of Study: approximately 29 months If you are interested in participating or learning more about our clinical trials, please call ESuarez@miamijewishhealth.org EDiaz1@miamijewishhealth.org
Improving diagnosis of Alzheimer s disease and lewy body dementia. Brain TLC October 2018
Improving diagnosis of Alzheimer s disease and lewy body dementia Brain TLC October 2018 Plan for this discussion: Introduction to AD and LBD Why do we need to improve diagnosis? What progress has been
More informationRoche satellite symposium/educational session CTAD Asia - China Conference Transforming AD in China: From Diagnosis to Treatment
Roche satellite symposium/educational session CTAD Asia - China Conference Transforming AD in China: From Diagnosis to Treatment Sunday 2 September 2018 Location: Shanghai, China NP/AZD/1807/0003 Complex
More informationCTAD 2017 Highlights, November 3-4
CTAD 2017 Highlights, November 3-4 The improved understanding of mechanisms underlying the development of AD, and thus the identification of new treatment targets, has largely been driven by genetic studies.
More informationNeuro degenerative PET image from FDG, amyloid to Tau
Neuro degenerative PET image from FDG, amyloid to Tau Kun Ju Lin ( ) MD, Ph.D Department of Nuclear Medicine and Molecular Imaging Center, Chang Gung Memorial Hospital ( ) Department of Medical Imaging
More informationAlzheimer s Disease without Dementia
Alzheimer s Disease without Dementia Dr Emer MacSweeney CEO & Consultant Neuroradiologist Re:Cognition Health London Osteopathic Society 13 September 2016 Early diagnosis of Alzheimer s Disease How and
More information3/7/2017. Alzheimer s and Dementia Research: An Advanced Discussion. Alzheimer s and Dementia Research: An Advanced Discussion
Alzheimer s and Dementia Research: An Advanced Discussion Brad Boeve, MD Department of Neurology Mayo Clinic Alzheimer s and Dementia Research: An Advanced Discussion Theoretical Constructs in Aging/Dementia
More informationDementia is a syndrome composed
Intense Focus Yet Many Setbacks for Alzheimer s Disease Drug Development Troy Kish, PharmD, BCPS Dementia is a syndrome composed of a variety of neurological deficits and impairments that affect memory,
More informationDementia Basics. Welcome! What to expect and how to handle a dementia diagnosis. In partnership with Scripps Health.
Dementia Basics What to expect and how to handle a dementia diagnosis March 18, 2017 In partnership with Scripps Health Welcome! 1 Welcome Kristin Gaspar San Diego County Supervisor District 3 2 Our Mission:
More informationSHANKER N. DIXIT, MD
Neurology Center of Las Vegas 2480 Professional Ct. Las Vegas, NV 89128 Phone: (702) 405-7100 EDUCATION SHANKER N. DIXIT, MD 1995 Medical: AIIMS, New Delhi, India, DM (Neurology) 1991 Medical: Kasturba
More informationStephen Salloway, M.D., M.S. Disclosure of Interest
Challenges in the Early Diagnosis of Alzheimer s Disease Stephen Salloway, MD, MS Professor of Neurology and Psychiatry Alpert Medical School, Brown University 2 nd Annual Early Alzheimer s Educational
More informationAlzheimer Clinical Trials: History and Lessons
Alzheimer Clinical Trials: History and Lessons Jeffrey Cummings, MD, ScD Center for Neurodegeneration and Translational Neuroscience Cleveland Clinic Lou Ruvo Center for Brain Health Disclosures Dr. Cummings
More informationBioArctic announces detailed results of the BAN2401 Phase 2b study in early Alzheimer s disease presented at AAIC 2018
Press release BioArctic announces detailed results of the BAN2401 Phase 2b study in early Alzheimer s disease presented at AAIC 2018 Stockholm, Sweden, July 25, 2018 BioArctic AB (publ) (Nasdaq Stockholm:
More informationFOR IMMEDIATE RELEASE July 26, 2018 Eisai Co., Ltd. Biogen Inc.
FOR IMMEDIATE RELEASE July 26, 2018 Eisai Co., Ltd. Biogen Inc. EISAI AND BIOGEN ANNOUNCE DETAILED RESULTS OF PHASE II CLINICAL STUDY OF BAN2401 IN EARLY ALZHEIMER S DISEASE AT ALZHEIMER S ASSOCIATION
More informationDEVELOPING TOPICS AT AAIC 2013 SHOW CUTTING EDGE BRAIN IMAGING TECHNIQUES, REVEAL PROBLEMS WITH SCREENING AND MISDIAGNOSIS
Contact: Alzheimer s Association media line: 312.335.4078, media@alz.org AAIC 2013 press room, July 13-18: 617.954.3414 DEVELOPING TOPICS AT AAIC 2013 SHOW CUTTING EDGE BRAIN IMAGING TECHNIQUES, REVEAL
More informationToday s Conversation. What's New in Dementia Research and Care? Our vision is a world without Alzheimer s disease
Today s Conversation What's New in Dementia Research and Care? Heather M. Snyder, Ph.D. Medical & Scientific Relations Sam Fazio, Ph.D. Constituent Services Who We Are Alzheimer s Association International
More informationMolecular Imaging and the Brain
Molecular imaging technologies are playing an important role in neuroimaging, a branch of medical imaging, by providing a window into the living brain. Where CT and conventional MR imaging provide important
More informationDISCLOSURES. Objectives. THE EPIDEMIC of 21 st Century. Clinical Assessment of Cognition: New & Emerging Tools for Diagnosing Dementia NONE TO REPORT
Clinical Assessment of Cognition: New & Emerging Tools for Diagnosing Dementia DISCLOSURES NONE TO REPORT Freddi Segal Gidan, PA, PhD USC Keck School of Medicine Rancho/USC California Alzheimers Disease
More informationAlzheimer s Disease Update: From Treatment to Prevention
Alzheimer s Disease Update: From Treatment to Prevention Jeffrey M. Burns, MD Edward H. Hashinger Professor of Medicine Co-Director, KU Alzheimer s Disease Center Director, Clinical and Translational Science
More informationAssessing and Managing the Patient with Cognitive Decline
Assessing and Managing the Patient with Cognitive Decline Center of Excellence For Alzheimer s Disease for State of NY Capital Region Alzheimer s Center of Albany Medical Center Earl A. Zimmerman, MD Professor
More informationOutline. Facts and figures Action plans Early / correct diagnosis Conclusions
Outline Facts and figures Action plans Early / correct diagnosis Conclusions Dementia: the greatest chalenge. Time to act now Philip Scheltens Professor of Neurology VU University Medical Center Amsterdam
More informationBioArctic announces positive topline results of BAN2401 Phase 2b at 18 months in early Alzheimer s Disease
Press release BioArctic announces positive topline results of BAN2401 Phase 2b at 18 months in early Alzheimer s Disease The full 18 month analysis of the 856 patient BAN2401 Phase 2b clinical study in
More informationDEMENTIA? 45 Million. What is. WHAT IS DEMENTIA Dementia is a disturbance in a group of mental processes including: 70% Dementia is not a disease
What is PRESENTS DEMENTIA? WHAT IS DEMENTIA Dementia is a disturbance in a group of mental processes including: Memory Reasoning Planning Learning Attention Language Perception Behavior AS OF 2013 There
More informationThe Aging Brain The Aging Brain
The Aging Brain The Aging Brain R. Scott Turner, MD, PhD Director, Memory Disorders Program Professor, Department of Neurology Georgetown University Washington, DC memory.georgetown.edu rst36@georgetown.edu
More informationEvaluation and Treatment of Dementia
Evaluation and Treatment of Dementia Jeffrey M. Burns, MD Edward H. Hashinger Professor of Neurology Co-Director, KU Alzheimer s Disease Center Director, Clinical and Translational Science Unit Disclosures
More informationOutline of Lecture 2/13/2018
Allan I. Pack, M.B.Ch.B., Ph.D., FRCP John Miclot Professor of Medicine Director, Center for sleep and Circadian Neurobiology University of Pennsylvania Perelman School of Medicine Philadelphia, Pennsylvania
More informationDefeating Alzheimer disease and dementia when will we get the cure?
Defeating Alzheimer disease and dementia when will we get the cure? Bengt Winblad Karolinska Institutet, Dept NVS Center for Alzheimer Research Div of Neurogeriatrics Huddinge, Sweden Demensdagene Copenhagen,
More informationThe ABCs of Dementia Diagnosis
The ABCs of Dementia Diagnosis Dr. Robin Heinrichs, Ph.D., ABPP Board Certified Clinical Neuropsychologist Associate Professor, Psychiatry & Behavioral Sciences Director of Neuropsychology Training What
More informationResearch and possible future brain health treatments
Research and possible future brain health treatments Cheryl Brandi, DNSc, ARNP, NP-C Roskamp Institute Clinic July 21, 2016 brandi, roskamp institute 1 The Roskamp Institute Not for profit biomedical research
More informationBiogen, Cambridge, MA, USA; 2 Cytel, Cambridge, MA, USA; 3 Neurimmune, Schlieren-Zurich, and University of Zurich, Switzerland
Aducanumab 36-Month Data From PRIME: A Randomized, Double-Blind, Placebo-Controlled Phase 1b Study in Patients With Prodromal or Mild Alzheimer s Disease Samantha Budd Haeberlein, PhD 1, Sarah Gheuens,
More informationAGITATION IN DEMENTIA BEHAVIORAL AND PSYCHIATRIC SYMPTOMS IN DEMENTIA (BPSD) AGITATION SUBGROUP SESSION 20 TH FEBRUARY 2018.
AGITATION IN DEMENTIA BEHAVIORAL AND PSYCHIATRIC SYMPTOMS IN DEMENTIA (BPSD) AGITATION SUBGROUP SESSION 20 TH FEBRUARY 2018. BRIEF OVERVIEW: AGITATION ASSOCIATED WITH ALZHEIMER S DISEASE (AD) AD afflicts
More informationDementia Update. October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada
Dementia Update October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada Outline New concepts in Alzheimer disease Biomarkers and in vivo diagnosis Future trends
More informationAmyloid and the Vessels. David Weisman, M.D.
Amyloid and the Vessels David Weisman, M.D. CMA I conduct Alzheimer/amyloid clinical research in conjunction with: Toyoma, ADRC, Genentech, Eisai, Envivo, Accera, Elan, Merck. Previously served on speaker
More informationMOVEMENT DISORDERS AND DEMENTIA
MOVEMENT DISORDERS AND DEMENTIA FOCUS ON DEMENTIA WITH LEWY BODIES MADHAVI THOMAS MD NORTH TEXAS MOVEMENT DISORDERS INSTITUTE, INC DEMENTIA de men tia dəˈmen(t)sh(ē)ə/ nounmedicine noun: dementia a chronic
More informationMild Cognitive Impairment
Mild Cognitive Impairment Victor W. Henderson, MD, MS Departments of Health Research & Policy (Epidemiology) and of Neurology & Neurological Sciences Stanford University Director, Stanford Alzheimer s
More informationDIET, AGING, and MIND. Neal G. Simon, Ph. D. Dept. of Biological Sciences Lehigh University
DIET, AGING, and MIND Neal G. Simon, Ph. D. Dept. of Biological Sciences Lehigh University Outline: Diet, Aging, and Mind 1. Brain Changes in Aging 2. Dementias 3. Dietary Interventions: DHEA and Soy 4.
More informationPROSPERO International prospective register of systematic reviews
PROSPERO International prospective register of systematic reviews Efficacy and safety of amyloid-beta immunotherapy for Alzheimer's disease: systematic review Marwa El-toukhy, Mohamed Zalabia, Ahmed Raslan,
More informationAAIC 2018, Chicago, Illinois, US. July 22, 2018
24-Month Analysis of Change From Baseline In Clinical Dementia Rating Scale Cognitive and Functional Domains in PRIME, A Randomized Phase b Study of the Anti-Amyloid Beta Monoclonal Antibody Aducanumab
More informationWhat if it s not Alzheimer s? Update on Lewy body dementia and frontotemporal dementia
What if it s not Alzheimer s? Update on Lewy body dementia and frontotemporal dementia Dementia: broad term for any acquired brain condition impairing mental function such that ADLs are impaired. Includes:
More informationOverview of neurological changes in Alzheimer s disease. Eric Karran
Overview of neurological changes in Alzheimer s disease Eric Karran Alzheimer s disease Alois Alzheimer 1864-1915 Auguste D. 1850-1906 Case presented November 26 th 1906 Guildford Talk.ppt 20 th March,
More informationDementia. Jeanette Norden, Ph.D. Professor Emerita Vanderbilt University School of Medicine
Dementia Jeanette Norden, Ph.D. Professor Emerita Vanderbilt University School of Medicine What is Dementia? Dementia is a general term referring to a decline in cognitive/mental functioning; this decline
More informationDementia, Cognitive Aging Services and Support
Dementia, Cognitive Aging Services and Support Ronald C. Petersen, Ph.D., M.D. Professor of Neurology Mayo Clinic College of Medicine Rochester, MN NASUAD Washington September 2, 2015 Disclosures Pfizer,
More informationA perspective on preclinical Alzheimer's disease trials
A perspective on preclinical Alzheimer's disease trials Pierre N. Tariot, MD Director, Banner Alzheimer s Institute Co-Director, API Research Professor of Psychiatry University of Arizona Disclosures I
More informationPromising drugs in development for Alzheimer s Disease
Promising drugs in development for Alzheimer s Disease Rupert McShane Oxford Health NHS Foundation Trust University of Oxford, Department of Psychiatry Prime Ministers Challenge Diagnosis of 66% of
More informationSupportive Neurology: Valuing Increased Function and Improved QoL in Treatment of Non-Core Symptoms of Neurological Disease
Supportive Neurology: Valuing Increased Function and Improved QoL in Treatment of Non-Core Symptoms of Neurological Disease Ginger S. Johnson, PhD Vice President Defined Health Todd Sherer, PhD Chief Executive
More informationMild Behavioral Impairment (MBI): Symptoms, Prodrome, or False Alarm?
Mild Behavioral Impairment (MBI): Symptoms, Prodrome, or False Alarm? Constantine G. Lyketsos, MD, MHS Chair of Psychiatry, Johns Hopkins Bayview Elizabeth Plank Althouse Professor, Johns Hopkins University
More informationDementia Facts and Resources Dementia Warning Signs Getting a Diagnosis Dementia Communication Tips Dementia Risk Reduction.
Dementia Facts and Resources Dementia Warning Signs Getting a Diagnosis Dementia Communication Tips Dementia Risk Reduction Intermission Dementia Stages and Behaviors Caregiving and Self-Care Overview
More informationA BRIEF LOOK AT DEMENTIA
Dementia A BRIEF LOOK AT DEMENTIA David Kaufman, MD Neurology Consultants of Bellin Health November 2, 2017 Defined as a progressive decline in cognitive function that impairs daily activities. Always
More informationAlzheimer's disease (AD), also known as Senile Dementia of the Alzheimer Type (SDAT) or simply Alzheimer s is the most common form of dementia.
CHAPTER 3 Alzheimer's disease (AD), also known as Senile Dementia of the Alzheimer Type (SDAT) or simply Alzheimer s is the most common form of dementia. This incurable, degenerative, terminal disease
More informationUnderstanding Symptoms, Causes, and Risks for Alzheimer s Disease
Understanding Symptoms, Causes, and Risks for Alzheimer s Disease Gene E. Alexander, Ph.D., Professor of Psychology, Neuroscience, and Physiological Sciences; Director, Brain Imaging, Behavior & Aging
More informationMemory Matters: Learning Objectives: Synapses, Age, and Health. Neuronal Synapses DISCLOSURE DECLARATION. Cognition and Normal Aging
Standard Deviations from Mean Memory Matters: Preventing and Treating Late-Life, Cognitive Decline Daniel L. Murman, MD, MS Director, Behavioral and Geriatric Neurology Program Professor & Vice Chair,
More informationAlzheimer's Disease A mind in darkness awaiting the drink of a gentle color.
Alzheimer's Disease A mind in darkness awaiting the drink of a gentle color. Mary ET Boyle, Ph. D. Department of Cognitive Science UCSD Gabriel García Márquez One Hundred Years of Solitude Alois Alzheimer
More information8/14/2018. The Evolving Concept of Alzheimer s Disease. Epochs of AD Research. Diagnostic schemes have evolved with the research
The Evolving Concept of Alzheimer s Disease David S. Geldmacher, MD, FACP Warren Family Endowed Chair in Neurology Department of Neurology UAB School of Medicine Epochs of AD Research Epoch Years Key Event
More informationPathogenesis of Degenerative Diseases and Dementias. D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria)
Pathogenesis of Degenerative Diseases and Dementias D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria) Dementias Defined: as the development of memory impairment and other cognitive deficits
More informationYin-Hui Siow MD, FRCPC Director of Nuclear Medicine Southlake Regional Health Centre
Yin-Hui Siow MD, FRCPC Director of Nuclear Medicine Southlake Regional Health Centre Today Introduction to CT Introduction to MRI Introduction to nuclear medicine Imaging the dementias The Brain ~ 1.5
More informationP20.2. Characteristics of different types of dementia and challenges for the clinician
P20.2. Characteristics of different types of dementia and challenges for the clinician, professor Danish Dementia Research Center Rigshospitalet, University of Copenhagen (Denmark) This project has received
More informationDementia: A Comprehensive Update Neuroimaging, CSF, and genetic biomarkers in dementia
Dementia: A Comprehensive Update 2016 Neuroimaging, CSF, and genetic biomarkers in dementia Bradford C. Dickerson, M.D. Associate Professor of Neurology, Harvard Medical School Departments of Neurology
More informationDr. Michael Lobatz Dr. Michael Jackson Dr. James Brewer Dr. Paul Aisen. Dr. Michael Plopper. Dr. Guerry Peavy
1 Anne State 2 3 Dr. Michael Lobatz Dr. Michael Jackson Dr. James Brewer Dr. Paul Aisen Dr. Michael Plopper Dr. Guerry Peavy 4 Michael Lobatz, MD Medical Director, Neurosciences Medical Director, Rehabilitation
More informationCURRICULUM VITAE Intern in Medicine, Beth Israel Hospital, Harvard Medical School, Boston, MA
Bruce D. Kohrman, M.D. 12305 SW 69 th Place Miami, Florida 33156 Telephone: (305) 903-8678 Fax: (305) 661-1672 CURRICULUM VITAE EDUCATION 1977 - B.S. Stanford University, Stanford, CA 1982 - M.D. Case
More informationAlzheimer s Disease. Fact Sheet. Fact Sheet. Fact Sheet. What Causes AD?
2 Alzheimer s Disease Dementia is a brain disorder that seriously affects a person s ability to carry out daily activities. The most common form of dementia among older people is Alzheimer s disease (AD),
More informationRanjan Duara, MD, FAAN
Ranjan Duara, MD, FAAN Medical Director, Wien Center for Alzheimer s Disease and Memory Disorders, Mount Sinai Medical Center, Miami Beach Clinical Professor of Neurology, Herbert Wertheim College of Medicine,
More informationCarol Manning, PhD, ABPP-CN Director, Memory Disorders Clinic University of Virginia
Carol Manning, PhD, ABPP-CN Director, Memory Disorders Clinic University of Virginia Case Study Mr. S. is a 74 year old man who has smoked for 20 years. He is overweight, has high cholesterol and high
More informationNovember 16-18, 2017 Hotel Monteleone New Orleans, LA. Provided by
November 16-18, 2017 Hotel Monteleone New Orleans, LA Provided by Treatment Targets in Alzheimer s Disease W. Vaughn McCall, MD, MS Professor and Case Distinguished University Chairman Department of Psychiatry
More informationNew life Collage of nursing Karachi
New life Collage of nursing Karachi Presenter: Zafar ali shah Faculty: Raja khatri Subject: Pathophysiology Topic :Alzheimer s Disease Post RN BScN semester 2 nd Objective Define Alzheimer s Describe pathophysiology
More informationALZHEIMER'S DISEASE PREVENTION TRIALS
ALZHEIMER'S DISEASE PREVENTION TRIALS Laurie Ryan, PhD Chief, Dementias of Aging Branch & Program Director, Alzheimer s Disease Clinical Trials Division of Neuroscience National Institute on Aging/National
More informationImpact of vitamins & nutrients on neurological function. B-vitamins and aging. Nafisa Jadavji, PhD
Impact of vitamins & nutrients on neurological function B-vitamins and aging Nafisa Jadavji, PhD nafisa.jadavji@carleton.ca Lecture Outline Answer to questions from last class Homocysteine Vitamin B9:
More informationREFERENCE CODE GDHC98PIDR PUBLICATION DATE FEBRUARY 2015 ALZHEIMER S DISEASE GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC98PIDR PUBLICATION DATE FEBRUARY 2015 ALZHEIMER S DISEASE GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2023 Executive Summary Table below presents the key metrics for Alzheimer s disease
More informationParkinson s Disease in the Elderly A Physicians perspective. Dr John Coyle
Parkinson s Disease in the Elderly A Physicians perspective Dr John Coyle Overview Introduction Epidemiology and aetiology Pathogenesis Diagnosis and clinical features Treatment Psychological issues/ non
More informationInception, Total Recall, & The Brain: An Introduction to Neuroscience Part 2. Neal G. Simon, Ph.D. Professor Dept. of Biological Sciences
Inception, Total Recall, & The Brain: An Introduction to Neuroscience Part 2 Neal G. Simon, Ph.D. Professor Dept. of Biological Sciences http://www.youtube.com/watch?v=wfmlgeh dije Summary from September
More informationFirst Scientific Symposium Translational Research in Alzheimer. Paris - September 18, 2009 Collège de France
First Scientific Symposium Translational Research in Alzheimer Paris - September 18, 2009 Collège de France 8h30 Welcome coffee 9h-9h30 Opening remarks - Philippe Lagayette, President of French National
More informationNutraceuticals & Lifestyle Changes That Can Halt The Progression Of Alzheimer s. by Dr. Gregory Smith
Nutraceuticals & Lifestyle Changes That Can Halt The Progression Of Alzheimer s by Dr. Gregory Smith DIET: Studies of dietary influences on Alzheimer's disease do not yet provide clear evidence. Also the
More informationWHO, WHAT, WHEN AND WHERE OF PARKINSON S DIAGNOSIS. MJFF Third Thursdays Webinar March 17, 2016
WHO, WHAT, WHEN AND WHERE OF PARKINSON S DIAGNOSIS MJFF Third Thursdays Webinar March 17, 2016 WHAT WE LL COVER TODAY How is Parkinson s misdiagnosed? How is Parkinson s diagnosed today? Can we use DaTscan
More informationWhat is Neuropsychology?
Alzheimer s Disease Neurological Bases and Informed Behavioral Interventions Peter T. Keenan Clinical Neuropsychologist Marshfield Clinic Minocqua Center What is Neuropsychology? Science of the relationship
More informationALZHEIMER S DISEASE. Mary-Letitia Timiras M.D. Overlook Hospital Summit, New Jersey
ALZHEIMER S DISEASE Mary-Letitia Timiras M.D. Overlook Hospital Summit, New Jersey Topics Covered Demography Clinical manifestations Pathophysiology Diagnosis Treatment Future trends Prevalence and Impact
More informationWhat About Dementia? Module 8, Part B (With Dr Allison Lamont)
What About Dementia? Module 8, Part B (With Dr Allison Lamont) Slide 1 Module 8 Part B will address the question What about dementia? Several surveys of older people both in the UK and USA have shown that
More informationAlzheimer's Disease, Prevalence, and Caregiving
Alzheimer's Disease, Prevalence, and Caregiving Specific information in this year s Alzheimer s Disease Facts and Figures includes: Proposed guidelines for diagnosing Alzheimer s disease from the National
More informationDementia. Assessing Brain Damage. Mental Status Examination
Dementia Assessing Brain Damage Mental status examination Information about current behavior and thought including orientation to reality, memory, and ability to follow instructions Neuropsychological
More informationDementia NICE Guidelines Update. Key points for primary care - NICE guideline (June 2018 update ) 26 September 2018
Dementia NICE Guidelines Update Key points for primary care - NICE guideline (June 2018 update ) 26 September 2018 How NICE guidelines are reviewed Multidisciplinary guideline committee established Review
More informationThe Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing
The Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing. (AUSTRALIAN ADNI) July 2013 UPDATE Imaging Christopher Rowe MD Neuroimaging stream leader June 2013 The Australian Imaging Biomarkers
More informationDRUG THERAPY CHOICES FOR THE DEMENTED PATIENT Past, Present and Future
DRUG THERAPY CHOICES FOR THE DEMENTED PATIENT Past, Present and Future Daniel S. Sitar Professor Emeritus University of Manitoba Email: Daniel.Sitar@umanitoba.ca March 6, 2018 INTRODUCTION EPIDEMIOLOGY
More information2018 ALZHEIMER S DISEASE FACTS AND FIGURES. Includes a Special Report on the Financial and Personal Benefits of Early Diagnosis
2018 ALZHEIMER S DISEASE FACTS AND FIGURES Includes a Special Report on the Financial and Personal Benefits of Early Diagnosis About this report 2018 Alzheimer s Disease Facts and Figures is a statistical
More informationUCSF Memory and Aging Center 2016
UCSF Memory and Aging Center 2016 Best Practices in Mild Cognitive Impairment & Dementia Bruce L. Miller, MD A.W. and Mary Margaret Clausen Distinguished Professor in Neurology Director, Memory and Aging
More informationLongitudinal 148-Week Update of ANAVEX 2-73 Phase 2a Alzheimer s Disease Extension Study
Longitudinal 148-Week Update of ANAVEX 2-73 Phase 2a Alzheimer s Disease Extension Study CTAD October 2018 Harald Hampel, MD, PhD 1, Mohammad Afshar, MD, PhD 2, Frédéric Parmentier, PhD 2, Coralie Williams,
More informationImaging of Alzheimer s Disease: State of the Art
July 2015 Imaging of Alzheimer s Disease: State of the Art Neir Eshel, Harvard Medical School Year IV Outline Our patient Definition of dementia Alzheimer s disease Epidemiology Diagnosis Stages of progression
More informationTUESDAY, MARCH 26, 2019 WEDNESDAY, MARCH 27, 2019
KEY: PRE CONFERENCE SYMPOSIUM SPONSORED SYMPOSIUM SYMPOSIUM PLENARY LECTURE FORUM OTHER EVENT *PRE-REGISTRATION IS REQUIRED FOR THE INFORMAL NETWORKING WITH PROFESSOR LUNCH SESSION TUESDAY, MARCH 26, 2019
More informationCoordinating Care Between Neurology and Psychiatry to Improve the Diagnosis and Treatment of Parkinson s Disease Psychosis
Coordinating Care Between Neurology and Psychiatry to Improve the Diagnosis and Treatment of Parkinson s Disease Psychosis Jeff Gelblum, MD Senior Attending Neurologist Mt. Sinai Medical Center Miami,
More informationLa neurosonologia. Ecografia cerebrale e nuove applicazioni nelle malattie neurodegenerative. Nelle patologie degenerative e vascolari cerebrali
La neurosonologia Nelle patologie degenerative e vascolari cerebrali Andrea Pilotto Ecografia cerebrale e nuove applicazioni nelle malattie neurodegenerative Prof. Daniela Berg Department of Neurodegeneration
More informationTUESDAY, MARCH 26, 2019 WEDNESDAY, MARCH 27, 2019
KEY: PRE CONFERENCE SYMPOSIUM SPONSORED SYMPOSIUM SYMPOSIUM PLENARY LECTURE FORUM OTHER EVENT *PRE-REGISTRATION IS REQUIRED FOR THE INFORMAL NETWORKING WITH PROFESSOR LUNCH SESSION TUESDAY, MARCH 26, 2019
More informationDementia. Understanding 9/20/2010. Jan Robson Coordinator of the Alzheimer Society's Dementia Helpline
Understanding Dementia Jan Robson Coordinator of the Alzheimer Society's Dementia Helpline Marc Labrecque Provincial Coordinator of Programs and Services 1 Understanding Dementia What is dementia Alzheimer
More informationLearning Outcomes. To have a clear understanding of the term dementia, and current facts and statistics relating to dementia.
Learning Outcomes To have a clear understanding of the term dementia, and current facts and statistics relating to dementia. To be familiar with some of the common types of dementia. To understand what
More information11/12/2018. Acknowledgements. Risk factors for Alzheimer s disease
Is it Possible to Reduce My Risk for Alzheimer's Disease? An Overview of Current Risk Reduction Strategies Dorothy Farrar Edwards PhD, Professor of Medicine and Kinesiology Core Leader: Outreach, Recruitment
More informationChanging diagnostic criteria for AD - Impact on Clinical trials
Changing diagnostic criteria for AD - Impact on Clinical trials London, November 2014 Bruno Dubois Head of the Dementia Research Center (IMMA) Director of INSERM Research Unit (ICM) Salpêtrière Hospital
More informationAlzheimer s Biomarkers Consortium of Down Syndrome (ABC-DS)
Alzheimer s Biomarkers Consortium of Down Syndrome (ABC-DS) AN OVERVIEW (with material provided by Ben Handen & Nicole Schupf) https://www.nia.nih.gov/research/abc-ds Alzheimer s Biomarkers Consortium
More informationFact Sheet Alzheimer s disease
What is Alzheimer s disease Fact Sheet Alzheimer s disease Alzheimer s disease, AD, is a progressive brain disorder that gradually destroys a person s memory and ability to learn, reason, make judgements,
More informationALZHEIMER S & DIABETES WHAT IS THE CONNECTION?
ALZHEIMER S & DIABETES WHAT IS THE CONNECTION? Quiz: True or False? Alzheimer s disease can not be diagnosed without an autopsy of brain tissue. Today there are medications that cure Alzheimer s disease.
More informationSummary of Risk Management Plan (RMP)
Summary of Risk Management Plan (RMP) Neuraceq Florbetaben ( 18 F), solution for injection SWAN Isotopen AG CH-3010 Bern The Risk Management Plan (RMP) is a comprehensive document submitted as part of
More informationInfiltrative Brain Mass Due To Progressive Alzheimer's Disease
Article ID: WMC00505 2046-1690 Infiltrative Brain Mass Due To Progressive Alzheimer's Disease Corresponding Author: Dr. Mark Lyons, Associate Professor, Mayo Clinic Arizona, 85054 - United States of America
More informationWHEN THE GOING GETS TOUGH: Working Through the Challenges of Dementia Together. Presented by
WHEN THE GOING GETS TOUGH: Working Through the Challenges of Dementia Together Presented by Our agenda for today Understanding behavioral symptoms in people living with dementia Briefly review key strategies
More informationHOW NUTRITION CHANGES THE AGING BRAIN. Nafisa Jadavji, PhD
HOW NUTRITION CHANGES THE AGING BRAIN Nafisa Jadavji, PhD NafisaJadavji@carleton.ca Lecture Outline Introduction Brain Nutrition Peer Review Questions BREAK Dementia and Alzheimer's disease Parkinson s
More informationTHE DEMENTIAS. Hope Through Research. LEARN ABOUT: Types of dementia Risk factors Diagnosis and treatment Current research
THE DEMENTIAS Hope Through Research LEARN ABOUT: Types of dementia Risk factors Diagnosis and treatment Current research National Institute of Neurological Disorders and Stroke National Institute on Aging
More information